This bill’s operative move is a repeal: Section 2 wipes out Section 704(b)(12) of the Office of National Drug Control Policy Reauthorization Act of 1998 (21 U.S.C. 1703(b)(12)). The text does not add replacement provisions or new authorities, funding, or mandates.
It is intentionally narrow: the bill names itself the Evidence-Based Drug Policy Act of 2025, but it does not detail any new evidence-building programs or policy actions.
Because the repeal is the sole action in the text, the bill offers no explicit policy direction beyond removing the prior constraint. The practical impact, therefore, will depend on how federal agencies and Congress respond in later legislation or through administrative action.
In other words, the bill signals a potential shift toward less prescriptive governance, but it does not specify what replaces the repealed requirement or how effectiveness will be demonstrated.
At a Glance
What It Does
The bill repeals Section 704(b)(12) of the ONDCP Reauthorization Act of 1998 (21 U.S.C. 1703(b)(12)). This repeal is the bill’s sole operative change.
Who It Affects
Federal agencies that implement national drug policy (including ONDCP and its sister agencies such as HHS and DOJ) and congressional committees overseeing drug policy.
Why It Matters
Removing a specific statutory constraint could alter how drug policy is designed and evaluated, but with no new obligations or funding, the practical effects are uncertain and depend on future action by lawmakers and agencies.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The act is a short, technical measure with a single, clear action: it repeals a particular provision of the 1998 ONDCP Reauthorization Act. The repeal targets Section 704(b)(12) (21 U.S.C. 1703(b)(12)).
The bill does not introduce new authorities, funding streams, or policy mandates. It instead relies on the existing framework to operate without that constraint, and it provides no replacement mechanism within the text.
As introduced, the bill does not specify any new processes, data collection, or governance standards to take the place of the repealed text. For compliance officers and policy analysts, the key takeaway is that the statutory constraint is removed, creating potential flexibility but also ambiguity about governance, accountability, and evidence-building measures that might be expected under an “Evidence-Based” label.
The outcome will hinge on subsequent policy actions, not on this bill alone.
The Five Things You Need to Know
The bill repeals Section 704(b)(12) of the ONDCP Reauthorization Act of 1998 (21 U.S.C. 1703(b)(12)).
No new authorities, mandates, or funding are added in the text of the bill.
The short title is the Evidence-Based Drug Policy Act of 2025.
Rep. Dina Titus (D) sponsors the bill with Rep. Ilhan Omar as co-sponsor; introduced April 29, 2025.
The text uses “for other purposes” but does not specify any additional changes in this bill.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title and citation
Section 1 designates the act as the Evidence-Based Drug Policy Act of 2025. It provides the formal naming and citation for this bill without altering policy provisions.
Repeal of Section 704(b)(12)
Section 2 repeals Section 704(b)(12) of the ONDCP Reauthorization Act of 1998 (21 U.S.C. 1703(b)(12)). The repeal is the only operative action in the bill and does not include replacement provisions or new authorities.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- ONDCP leadership and staff gain flexibility in policy implementation due to the removal of a constraint.
- Federal agencies that implement national drug policy (such as HHS, DOJ, and related components) may experience reduced prescriptive burdens and greater discretion in policy execution.
- Congressional oversight committees may face fewer regulatory burdens related to this provision, potentially simplifying monitoring.
- Policy researchers and advocacy groups favoring streamlined governance may view the repeal as aligning policy development with a more flexible framework.
Who Bears the Cost
- Public health and civil society advocates who rely on accountability and transparency mechanisms embedded in the repealed provision may perceive reduced safeguards.
- State and local agencies that align with federal drug policy guidance might face uncertainty during transition if the repealed rule previously provided a clear benchmark.
- Federal watchdogs and GAO-style evaluators could encounter fewer data requirements for program review, complicating performance assessment.
- Taxpayers could bear indirect costs if the policy landscape becomes less predictable and necessitates later corrective legislation.
Key Issues
The Core Tension
The central dilemma is whether removing a statutory constraint will yield more agile, evidence-informed policy or erode the checks and accountability that ensure drug policy changes are demonstrably effective.
The repeal removes a statutory constraint within the ONDCP framework, but the bill provides no alternative governance or reporting mechanism. That absence creates a potential gap in accountability and in the ability to demonstrate evidence-based outcomes, which is at odds with the bill’s title.
In practice, the effect will depend on whether agencies publish new guidance, Congress enacts follow-up legislation, or agencies pursue independent evaluation strategies to substitute for the repealed constraint. The risk is that without a replacement structure, there may be more policy discretion but less structured evidence gathering and public accountability.
Two broad tensions emerge: flexibility versus accountability, and speed versus rigor. Removing the constraint could speed policy action, but it may also reduce the formal triggers for evaluation and reporting that help ensure decisions are grounded in evidence.
The bill’s silence on replacements means stakeholders must watch for additional legislation or regulatory actions that restore or redefine the governance safeguards that the repealed subsection may have supported.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.